Anti Diarrheal Drugs Market Size Estimated to Reach $290 Million by 2025

Anti-Diarrheal Drugs Market size is estimated to reach $290m by 2025 and is poised to grow at a CAGR of 2.7% during the forecast period 2020-2025. Antidiarrheal drugs are used to treat abrupt diarrhea and possess the mechanism of slowing down the movement of the gut and helps to diminish the number of bowel movements and make the stools less watery. Distinct causes of diarrhea can be a virus such as a rotavirus, hepatitis, a bacterium such as E.coli, Shigella, and parasites causing amoebiasis and giardiasis. Majority of the events of diarrhea are recognized to be concluded with simple dietary modifications and not require treatment, however, in certain cases of severe diarrhea, laboratory assessment is requisite which includes blood tests, and stool specimen evaluation to analyze the type of diarrhea. The increasing incidence of the diarrheal disease is creating a demand for Antidiarrheal Drugs, thereby, leading to market growth.

Full Report Link @ https://www.industryarc.com/Report/17439/anti-diarrheal-drugs-market.html

By Type- Segment Analysis

The global Anti-Diarrheal Drugs market based on the type has OTC Drugs, Prescription Drugs, and others. OTC Drugs registered high revenue in the year 2019 and is poised to grow for the forecast period (2020-2025). The growth is owing to the growing demand for personalized medicine for treating minor ailments and introduction of treatment protocols by healthcare payers.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=17439
Report Price: $ 4500 (Single User License)

By Application – Segment Analysis

The global Anti-Diarrheal Drugs market based on end-use, can be further segmented into adults, children, and others. Children segment was on top in terms of revenue in the year 2019 and is poised to grow during the forecast period (2020-2025). According to the WHO, diarrhea is the second leading cause of death, especially in children less than 5 years of age. Moreover, diarrhea is known to be a major cause of malnutrition in children, since the disease deprives the child of the nutrition required for their proper growth.

By Geography - Segment Analysis

North America had the major share of market in the year 2019. This is owing to high prevalence of diarrhea and higher adoption rate for antidiarrheal drugs. Furthermore, Asia-Pacific is estimated to experience rapid growth during the forecast period 2020-2025, wherein emerging economies such as China and India are the key consumers of antidiarrheal drugs owing to unhygienic and improper sanitation procedures, increasing awareness and infrastructure.

Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=17439

Drivers – Anti-Diarrheal Drugs Market

Rise in Diarrheal disease

The Anti-Diarrheal Drugs market is poised to grow owing to increasing incidence of the diarrheal disease. The various factors that are driving the global antidiarrheal drugs market are rising government initiatives for improvement in healthcare facilities, growing awareness for antidiarrheal drugs, and increasing prevalence for diarrhea cases.

Challenges – Anti-Diarrheal Drugs Market

Side effects of Anti-Diarrheal drugs

Various side effects associated with the uptake of antidiarrheal drugs, such as constipation, fullness and bloating are restraining the global antidiarrheal drugs market. In addition, traditional and home remedies are still popular in emerging countries. This controlled the market for Anti-Diarrheal Drugs.

Anti-Diarrheal Drugs Market Industry outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anti-Diarrheal Drugs Market. Key companies of this market GlaxoSmithKline, Proctor & Gamble, Pfizer, Actelion, Perrigo, Lupin, Glenmark Pharmaceuticals, Sanofi Aventis, Merck & Co., Novartis.

Acquisitions/Product Launches

In February 2020, Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris Seasonal Allergic Rhinitis Spray in the US.
In December 2019, Sanofi Aventis and Regeneron Pharmaceuticals, Inc today announced their intent to simplify their antibody collaboration for Kevzara and Praluent by restructuring into a royalty-based agreement.

Key Takeaways

Geographically, the North America area is poised to see extraordinary development owing to high prevalence of diarrhea and higher adoption rate for antidiarrheal drugs and is set to continue during the forecast period (2020-2025).

The increasing incidence of the diarrheal disease is creating a demand for Anti diarrheal Drugs, thereby, leading to market growth during the forecast period 2020-2025.

Various side effects associated with the uptake of antidiarrheal drugs, such as constipation, fullness and bloating are restraining the global antidiarrheal drugs market.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Anti-Diarrheal Drugs Market report.

Related Reports :

A. Antiemetic Drugs Market Analysis
https://www.industryarc.com/Report/15596/antiemetic-drugs-market.html

B. Antiepileptic Drugs Market
https://www.industryarc.com/Report/15597/antiepileptic-drugs-market.html

For more Lifesciences and Healthcare related reports @ https://www.industryarc.com/Domain/8/lifesciences-healthcare-market-research.html

Venkat Reddy
Sales Director
Email: venkat@industryarc.com
Website: https://www.industryarc.com
Phone: (+1) 970-236-3677

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

This release was published on openPR.